Researchers Reprogram Soft-Tumor Cells With CD19, Cutting CAR-T Resistance in Solid Tumors
Updated
Updated · BIOENGINEER.ORG · Jul 6
Researchers Reprogram Soft-Tumor Cells With CD19, Cutting CAR-T Resistance in Solid Tumors
3 articles · Updated · BIOENGINEER.ORG · Jul 6
Summary
Nature Biomedical Engineering reported that cancer cells conditioned by soft tumor matrices survived CAR-T attack better, but forcing those cells to express CD19 restored killing and reduced tumor burden in mouse xenografts.
Softness drove sustained calcium oscillations and higher extracellular ATP, which the team linked to a stem-like, therapy-resistant state marked by EMT, hypoxia, Wnt/Hedgehog signaling, CD44 and ALDH.
A doxycycline-gated calcium recorder, CaRMT, permanently labeled cells that had sensed soft environments, letting researchers isolate the resistant population across cell lines and patient-derived organoids.
The rewired “mechano-reprogrammer” swapped the fluorescent label for CD19, so only softness-responsive cells displayed the antigen and became targets for existing CD19 CAR-T cells.
The study suggests tumor mechanics can be turned from an immune-evasion niche into a programmable vulnerability, offering a synthetic-biology route to improve CAR-T therapy in solid cancers.
CAR T-cell therapy has transformed blood cancer treatment, but its use in solid tumors faces major challenges. Solid tumors develop ways to evade therapy, such as releasing TGF-β to suppress immune responses and promote tumor growth. These defenses make immunotherapies less effective and can cause CAR-T cells to fail, sometimes due to senescence. To overcome this, new strategies are being developed that target both the tumor’s physical defenses and the immune environment, aiming to make solid tumors more vulnerable and improve the long-term success of CAR-T cell therapy.